 |
| Gilead CEO John Martin |
Pharma CEOs are doing a pretty good job at the helm--at least where the Harvard Business Review is concerned. Four of them--Gilead Sciences' ($GILD) John Martin, Allergan's ($AGN) David Pyott, Novo Nordisk's ($NVO) Lars Rebien Sorensen and Valeant Pharmaceuticals' ($VRX) J. Michael Pearson--made the publication's top 10, ranked by their market cap growth and shareholder returns. More